Project Grant 2208609
Award Date 6/1/22
Completion Date 5/31/23
Dollars Obligated $256K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21231, USA
Similar Awards
- The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
- Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...
- Federal Project Grant Award Summary Award Details: Immuno Nano Med, Inc. received a $305,000 Phase I Small Business Technology Transfer (STTR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on October 1, 2025, with completion targeted for September 30, 2026. The award supports research and development activities at the company's Ames, Iowa facility. Products and Services: This STTR Phase I project will develop and demonstrate...
- This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
- Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...
- Federal Project Grant Award Summary Georgia TECH Research Corp received a $390,942 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 12, 2025, with a completion date of May 31, 2030. The project focuses on the research and development of self-assembled peptide nanoparticles (SAPNs) as a universal influenza vaccine platform. The research effort addresses the limitation...
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $460,625 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 9, 2026, with completion targeted for January 31, 2028. The award supports basic immunological research aimed at identifying and characterizing immune correlates associated with vaccine-induced protection...
- The National Science Foundation Division of Industrial Innovation awarded MBF Therapeutics Inc. a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) from January 1, 2022 to December 31, 2022. The grant funds the development of a protective T cell vaccine for SARS CoV-2 (COVID-19). The Engineering program supports innovation, creativity and excellence in engineering research and education to improve quality of life and economic strength. This award furthers those...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $661,313 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, for a research project titled "Elicitation of Pan-Influenza A Antibodies via Simple B Cell Development Pathways." Led by Principal Investigator Dr. Daniel Lingwood with Co-Investigators Dr. Batista and Dr. Andrew Ward, this R01 project will...
- Federal Project Grant Award Summary Abvacc, Inc. received a $638,953 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 22, 2025, with a completion date of July 31, 2030. The award supports development of an immunotherapeutic antibody cocktail for treatment of Staphylococcus aureus bacteremia (SAB). The research addresses a critical therapeutic gap, as no S. aureus...